MENU
+Compare
FATE
Stock ticker: NASDAQ
AS OF
Jun 6, 11:59 AM (EDT)
Price
$1.46
Change
+$0.12 (+8.96%)
Capitalization
153.61M

FATE Fate Therapeutics Forecast, Technical & Fundamental Analysis

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States... Show more

Industry: #Biotechnology
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for FATE with price predictions
Jun 05, 2025

FATE's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for FATE turned positive on May 20, 2025. Looking at past instances where FATE's MACD turned positive, the stock continued to rise in of 60 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 19, 2025. You may want to consider a long position or call options on FATE as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

FATE moved above its 50-day moving average on May 16, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FATE advanced for three days, in of 258 cases, the price rose further within the following month. The odds of a continued upward trend are .

FATE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 166 cases where FATE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FATE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.533) is normal, around the industry mean (16.332). P/E Ratio (0.000) is within average values for comparable stocks, (59.787). FATE's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.227). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (11.862) is also within normal values, averaging (263.647).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. FATE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FATE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

FATE is expected to report earnings to rise 20.56% to -38 cents per share on July 30

Fate Therapeutics FATE Stock Earnings Reports
Q2'25
Est.
$-0.39
Q1'25
Beat
by $0.07
Q4'24
Est.
$-0.44
Q3'24
Beat
by $0.02
Q2'24
Beat
by $0.13
The last earnings report on May 13 showed earnings per share of -31 cents, beating the estimate of -38 cents. With 794.74K shares outstanding, the current market capitalization sits at 153.61M.
A.I. Advisor
published General Information

General Information

a clinical stage biopharmaceutical company

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12278 Scripps Summit Drive
Phone
+1 858 875-1800
Employees
220
Web
https://www.fatetherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RTNSX13.030.02
+0.15%
Russell Inv Tax-Managed Intl Eq S
AASOX16.43N/A
N/A
Alger Small Cap Growth I-2
LIRSX9.36N/A
N/A
Lord Abbett International Value R4
SMRPX10.28N/A
N/A
Westwood Salient MLP & Engy Infras Ultr
SBQAX13.16N/A
N/A
AmericaFirst Alpha Trends Factor Class A

FATE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with ALLO. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
-5.63%
ALLO - FATE
57%
Loosely correlated
N/A
CRBU - FATE
55%
Loosely correlated
-3.54%
CRSP - FATE
54%
Loosely correlated
+1.37%
CCCC - FATE
52%
Loosely correlated
-4.87%
NTLA - FATE
52%
Loosely correlated
-1.30%
More